TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

4 Big-Volume Stocks to Trade for Breakouts: Crocs, Rovi and More
INVESTING

5 Stocks Under $10 Set to Soar

Ventas Sells Majority Stake in Ardent's Hospital Operations to Zell PE Firm
MERGERS AND ACQUISITIONS

Lundbeck to Buy Chelsea Therapeutics for $658M

Dating Sites: Best, Worst & Weirdest
MARKETS

Why Chelsea Therapeutics (CHTP) Stock Is Soaring Today

Dating Sites: Best, Worst & Weirdest
INVESTING

Chelsea Exits in Victory With Lundbeck Takeout

'Mad Money' Lightning Round: Apple Is Still Great and I'm Still Buying It
JIM CRAMER

'Mad Money' Lightning Round: Zynga Can Go Higher

Jim Cramer's 'Mad Money' Recap: Don't Panic
JIM CRAMER

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie
STOCKS

Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!

Dating Sites: Best, Worst & Weirdest
JIM CRAMER

Biotech Continues to Lead Market: Innovation and M&A

Dating Sites: Best, Worst & Weirdest
INVESTING

Chelsea Therapeutics Wins FDA Approval For Northera

Dating Sites: Best, Worst & Weirdest
INVESTING

Prediction: Chelsea Wins Northera FDA Approval Friday

Ariad Pharmaceutical's Iclusig May Relieve Shareholders' Pain: StockTwits
JIM CRAMER

J.P. Morgan Confab Focus Reminds Us Upside Remains In Biotech

Dating Sites: Best, Worst & Weirdest
INVESTING

A Few Minutes With Chelsea's CEO on Tuesday's Northera Panel and Future Plans

Chelsea Therapeutics: Northera FDA Panel Live Blog
INVESTING

Chelsea Therapeutics: Northera FDA Panel Live Blog

Dating Sites: Best, Worst & Weirdest
INVESTING

Chelsea Blues: FDA Reviewer Hates Northera But Don't Head For Exit Quite Yet (Corrected)

Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie
STOCKS

Biotech Stock Mailbag: NeoStem, MannKind, Inovio

Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study
STOCKS

Biotech Stock Mailbag: Inovio, Chelsea, Exelixis, Ariad, ImmunoCellular

Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?
STOCKS

Biotech 2013 by the Numbers: A Blockbuster Year

CTI Biopharma Posts Positive Myelofibrosis Study Results
STOCKS

2014 FDA Drug Approval Decision Calendar

'Free the Webcast!' Investor Transparency Gains Momentum at 'JPM15' Healthcare Confab
STOCKS

Biotech Stock Mailbag: Enanta, Vanda, Pharmacyclics, Top 2014 Stock Catalysts

Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest
STOCKS

Biotech Stock Mailbag: Chelsea's FDA Panel, Ariad's Future, Bio-Bubble Update

4 Huge Stocks on Traders' Radars
INVESTING

5 Biotech Stocks Under $10 for Your Watch List

4 Big-Volume Stocks to Trade for Breakouts: Crocs, Rovi and More
INVESTING

4 Biotech Stocks Under $10 on the Verge of Breakouts

3 Unusual-Volue Stocks on the Rise
INVESTING

4 Stocks Under $10 Making Big Moves

MannKind Afrezza Contributes to Sanofi's Subpar Diabetes Unit Sales
STOCKS

Biotech Stock Mailbag: Sarepta, Chelsea, IPO Fever

Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study
STOCKS

Five Best-Performing Biotech Stocks of 2013 (Some May Surprise You)